An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid ...
The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...
The rate of recurrent stroke was 4.6% in patients receiving the antihypertensive triple pill and 7.4% in those receiving ...
An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid ...
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...
STROKE trial show a 26% reduction in recurrent stroke with the factor XIa inhibitor asundexian, with no increased bleeding ...
Treatment with GMRx2, a single pill combination of three low-dose blood pressure medicines, significantly reduced the risk of ...
An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining the pounds they ...
After an intracerebral hemorrhage, patients had better BP control, fewer recurrent strokes, and a lower incidence of major ...
At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results